- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04588038
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
A Window of Opportunity Trial of NT-I7 in Patients With Locally Recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Salvage Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate safety and feasibility of a single intramuscular injection of efineptakin alfa (NT-I7) in patients with locally recurrent squamous cell carcinoma of head and neck (SCCHN).
SECONDARY OBJECTIVES:
I. To describe changes in absolute lymphocyte count (ALC) in peripheral blood after a single dose of NT-I7.
II. To describe changes in tumor infiltrating lymphocytes (TIL) in tumor microenvironment of surgical specimen after a single dose of NT-I7.
III. To evaluate changes in immune subsets in peripheral blood after a single dose of NT-I7 and after surgery.
EXPLORATORY OBJECTIVE:
I. To make assessment of exploratory biomarkers for pharmacodynamic activity of NT-I7 in peripheral blood, and/or tumor tissue.
OUTLINE:
Patients receive one dose of efineptakin alfa intramuscularly (IM).
After completion of study treatment, patients are followed up for 35 days after dose or 21 days after surgery.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California San Francisco
-
Principal Investigator:
- Hyunseok Kang, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed squamous cell carcinoma of oral cavity, oropharynx, hypopharynx or larynx with recurrent disease which is amenable for curative intent surgical resection
- Age >= 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Absolute neutrophil count >= 1,500/microliter (mcL)
- Platelets >= 100,000/mcL
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) =< 3 X institutional upper limit of normal
- Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase (SGPT) =< 3 X institutional upper limit of normal
- Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for subjects with documented liver involvement or bone metastases)
- Creatinine =< 1.5 x within institutional upper limit of normal OR
- Creatinine clearance glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2,calculated using the Cockcroft-Gault equation, unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2
- Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- The effects of NT-I7 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception for the duration of study participation and for 3 months after the study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation for 3 months after the study treatment
Exclusion Criteria:
- Had received immune check point inhibitor within 6 weeks prior to study entry OR chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry)
- Has history of autoimmune disease which requires active immune suppression (steroid replacement for iatrogenic deficiencies, prednisone 5 mg or less [or equivalent dose], or topical steroids are allowed)
- Is currently receiving any other investigational agents
- Has uncontrolled tumor-related pain
- Has uncontrolled intercurrent medical illness, including but not limited to congestive heart failure, recent acute cardiac event within 6 months, and recent major bleeding event within 6 months
- Pregnant women are excluded from this study because effects of NT-I7 on developing fetus is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with NT-I7, breastfeeding should be discontinued if the mother is treated with NT-I7
- Is not recovered from adverse events (AEs) (other than alopecia, vitiligo, neuropathy or endocrinopathy managed with replacement therapy) due to agents administered more than 4 weeks earlier (i.e., have residual toxicities > grade 1)
- Had major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to study initiation
- Had concurrent or previous other malignancy within 5 years of study entry, except noninvasive or indolent malignancy
- Has spinal cord compression not definitively treated with surgery and/or radiation
- Has active autoimmune diseases including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, vasculitis or glomerulonephritis
- Has active and clinically relevant bacterial, fungal, viral, or Tuberculosis (TB) infection, including known Hepatitis A, B, or C or human immunodeficiency virus (HIV) (testing not required) or have been hospitalized within 4 weeks prior to NT-I7 injection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (efineptakin alfa)
Patients receive one dose of efineptakin alfa IM.
|
Given via intramuscular injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of treatment-related adverse events
Time Frame: Up to 35 days after the after the NT-I7 injection
|
The proportion of patients experiencing grade 3 or 4 adverse events assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be reported with exact binomial 95% confidence intervals.
Safety analyses will be performed for all patients who receive a dose of NT-I7
|
Up to 35 days after the after the NT-I7 injection
|
Number of participants who completed course of NT-I7
Time Frame: Up to 43 days after the after the NT-I7 injection
|
Feasibility will be evaluated as the successful completion of pre-operative NT-I7 and proceeding to pre-planned surgery without any extended treatment-related delay defined as > 28 days from day 15.
A probability-based decision rule for the study will be used to decide if the probability of successfully proceeding to surgery as planned is convincingly less than .75
|
Up to 43 days after the after the NT-I7 injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Absolute lymphocyte count (ALC)
Time Frame: Up to 36 days after the NT-I7 injection
|
Descriptive changes in ALC in peripheral blood both before and after a single dose of NT-I7 will be recorded.
|
Up to 36 days after the NT-I7 injection
|
Changes in Tumor infiltrating lymphocytes (TIL)
Time Frame: Up to 15 days after the NT-I7 injection
|
Descriptive changes in tumor infiltrating lymphocytes in tumour microenvironment (TME) after a single dose of NT-I7 in pre-treatment biopsy and surgical specimen will be recorded.
|
Up to 15 days after the NT-I7 injection
|
Changes in immune phenotyping
Time Frame: Up to 36 days after the NT-I7 injection
|
Descriptive changes in immune phenotyping in peripheral blood after a single dose of NT-I7 and after surgery as measured by mass cytometry will be recorded.
|
Up to 36 days after the NT-I7 injection
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gene expression profiling: ribonucleic acid (RNA)-sequencing
Time Frame: Up to 36 days after the NT-I7 injection
|
Gene expression profiling by bulk ribonucleic acid (RNA)-sequencing or single cell RNA sequencing will be performed.
|
Up to 36 days after the NT-I7 injection
|
Gene expression profiling: T cell receptor (TCR)
Time Frame: Up to 36 days after the NT-I7 injection
|
Gene expression profiling by T cell receptor (TCR) diversity via TCR sequencing (TCRseq) will be performed.
|
Up to 36 days after the NT-I7 injection
|
Circulating cytokine analysis
Time Frame: Up to 36 days after the NT-I7 injection
|
Circulating cytokine analysis will be performed on serum samples.
|
Up to 36 days after the NT-I7 injection
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Hyunseok Kang, MD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202014
- NCI-2020-07340 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Head and Neck Squamous Cell Carcinoma
-
Ohio State University Comprehensive Cancer CenterRecruitingRecurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
Glenn J. HannaImmunityBio, Inc.RecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Washington University School of MedicineEli Lilly and CompanyRecruitingRecurrent Head and Neck Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | HNSCC | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLCRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
Shyam S.D. RaoNational Cancer Institute (NCI)RecruitingMetastatic Head and Neck Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Refractory Head and Neck Squamous Cell CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); AstraZenecaTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell CarcinomaUnited States
-
Novartis PharmaceuticalsTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell CarcinomaFrance, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
-
Washington University School of MedicineMerck Sharp & Dohme LLC; Joseph Sanchez FoundationActive, not recruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell CarcinomaUnited States
Clinical Trials on Efineptakin alfa
-
NeoImmuneTechNational Institute of Allergy and Infectious Diseases (NIAID); University of...Terminated
-
PT Kalbe Genexine BiologicsGenexine, Inc.Recruiting
-
Genexine, Inc.Terminated
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Cancer Immunotherapy Trials Network (CITN)TerminatedHIV Infection | Kaposi Sarcoma | AIDS-Related Kaposi SarcomaUnited States
-
NeoImmuneTechRecruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell LymphomaUnited States
-
NeoImmuneTechBristol-Myers SquibbTerminatedGastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)United States, Poland
-
NeoImmuneTechRoche Pharma AGActive, not recruitingCarcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small Cell Lung CarcinomaUnited States
-
NeoImmuneTechImmune Oncology NetworkTerminatedMelanoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States
-
Genexine, Inc.Active, not recruitingRecurrent GlioblastomaKorea, Republic of
-
NeoImmuneTechMerck Sharp & Dohme LLCActive, not recruitingSmall Cell Lung Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Microsatellite Stable Colorectal Cancer | Any Advanced Solid TumorsUnited States